**Supplementary**

**Methods**

**Data Source:**

TriNetX (Cambridge, MA, USA) cloud-based features allow real-time access to the de-identified longitudinal clinical data along with the analytics to analyze research questions. The de-identified clinical data is aggregated directly from the Electronic Health Record (EHR) of the participating or member HCOs continuously. Both the patients and HCO's as data sources stay anonymous. Participating HCO's include a mix of inpatient, outpatient, and specialty care services and provide care to a diverse patient population from different geographical regions. A typical HCO is a large academic health center with data coming from majority of its affiliates. A single HCO frequently has more than one facility, including main and satellite hospitals and outpatient clinics. In majority of cases, the data originates from the primary HER system. A typical organization has a complex enterprise architecture where the data flows through several different databases, such as a data warehouse and a research data repository, on its way to TriNetX. In addition to EHR data that is usually available in a structured fashion (e.g., demographics, diagnoses, procedures, medications, lab test results, vital signs). TriNetX has also the ability to extract facts of interest from the narrative text of clinical documents using Natural Language Processing (NLP). TriNetX maps the data to a standard and controlled set of clinical terminologies. The data is then transformed into a proprietary data schema. This transformation process includes an extensive data quality assessment that includes ‘data cleaning’ that rejects records that don’t meet the TriNetX quality standards.

TriNetX ensures HIPAA compliance of the clinical patient data. Depending on the HCO, the dataset is either de-identified or represents a Limited Data Set. Patient identifiers are always synthetic and are meant for research purposes. For de-identified data, dates are obfuscated. Ages over 90 are not revealed. TriNetX datasets do not include ZIP codes. TriNetX further protects PHI when generating and displaying results, with features such as rounded results, minimum cohort sizes, limited use of sensitive terms, etc.

**Data Quality Checks**

TriNetX software checks the basic formatting to ensure, for example, that dates are properly represented. It enforces a list of fields that are required (e.g., patient identifier) and rejects those records where the required information is missing. Referential integrity checking is done to ensure that data spanning multiple database tables can be successfully joined together. As the data is refreshed, the software monitors changes in volumes of data over time to ensure data validity. TriNetX requires at least one non-demographic fact for a patient to be counted in our dataset. Patient records with only demographics information are not included in datasets.

**Coding systems to present data**

Demographics are coded to HL7 version 3 administrative standards. Diagnoses are represented by ICD-10-CM codes.  If an HCO provides data in ICD-9-CM, data source uses a 9-to-10-CM mapping based on GEMs plus custom algorithms & curation to transform data from ICD-9-CM to ICD-10-CM.  Diagnoses data are enriched with the Chronic Condition indicator (CCI). Depending on the coding system used by an HCO, procedure data coded in ICD-10-PCS or CPT.  For many procedures, both ICD-10-PCS and CPT codes are added to a query to define a cohort. Medications are represented at level of ingredients, coded to RxNorm, and organized by NDF-RT Therapeutic Classes. Lab results, vitals, and findings are coded to LOINC. To ease finding and using common labs, LOINC codes are combined up to clinically significant level for most frequent labs and coded as TNX: LAB.

**Definition of Study Variables/Outcomes**

Any instance of Hospitalization occurring within 2 Weeks before or up to 1 Month after diagnosis of COVID-19 was considered as COVID-19 Hospitalization. COVID-19 Hospitalization and Hydroxychloroquine treatment were defined as the index event in the treatment group, while COVID-19 Hospitalization was the index event in the control group. Baseline comorbidities were estimated based on diagnosis any time before or at the time of index event. Laboratory findings were the most recent values after the index event. The main outcome of interest was the 30-day mortality and need for mechanical ventilation. The time window to estimate all outcomes were from the one day after to 30 days after the index event.

**Statistical Analysis**

All statistical analyses were performed using TriNetX platform custom developed solution purpose built for the clinical research domain. Java 1.8.0\_171, R 3.4.4 and Python 3.6.5 (along with their libraries/utilities for data science and statistics) software languages and packages are part of the statistical pipeline. TriNetX obfuscates patient counts to safeguard protected health information (PHI) by rounding patient counts in analyses up to the nearest 10. A 1:1 propensity score matching was performed using a greedy nearest-neighbor matching algorithm. For each outcome, the risk difference and risk ratio were calculated. A-priori defined two-sided alpha of less than <0.05 was used for statistical significance.

**eFigure 1:** Propensity Score Density Graph before and after propensity score matching of the Hydroxychloroquine treatment group and the control group.

